Drug Trial Radar · NCT05702983
The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: May 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Jan 31, 2023
Primary completion
Apr 11, 2023
Study completion Apr 24, 2023
Sponsor
- Lead sponsor
- Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 57 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An Open-label, Single-ascending dose, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STSA-1002 Subcutaneous Injection in Healthy Subjects
Conditions
- Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Interventions
STSA-1002 subcutaneous injectionDrug
Subjects will receive a single low dose on day 1 following protocol requirements.
STSA-1002 subcutaneous injectionDrug
Subjects will receive a single high dose on day 1 following protocol requirements.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of treatment-related adverse events as assessed by toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trialsTime frame: 50 days
- Abnormal clinical laboratory values as assessed by toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (blood hematology, blood chemistry, urinalysis, etc.)Time frame: 50 days
- Abnormal vital signs as assessed by toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (body temperature, pulse rate, blood pressure and respiratory rate)Time frame: 50 days
- Abnormal physical examinationTime frame: 50 days
- Abnormal electrocardiogram (ECG): heart rate, PR and QT intervals, QTcF and QRS durationTime frame: 50 days
- Maximum plasma concentration (Cmax)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
- area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
- area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
- Time of maximum concentration (Tmax)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
- elimination half-life (t1/2)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
- elimination rate constant of plasma drug concentration in terminal phase (λz)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
- last measurable concentration (Clast)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
- mean residence time (MRT)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
- clearance (CL)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
- apparent volume of distribution (Vz)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
AltaSciences Clinical Kansas, Inc
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.